Introduction
This article serves as a formal correction to a 2019 study published in the Journal of Experimental & Clinical Cancer Research. The primary objective is to rectify an image error in a western blot (specifically the CyclinD1 gel blot in Figure 5d). Beyond the technical correction, this update reinforces the study's critical findings regarding the molecular mechanisms that sustain Leukemia Stem Cells (LSCs) in Acute Myeloid Leukemia (AML).
The miR-29b/Sp1/FUT4 Regulatory Axis
AML is driven by a resilient population of LSCs that often survive standard chemotherapy, leading to disease relapse. This research identifies a specific biochemical pathway—the miR-29b/Sp1/FUT4 axis—that maintains the "stemness" and survival of these cells.
The central mechanism involves fucosylation, the enzymatic addition of fucose sugars to proteins. The enzyme FUT4 modifies the CD44 receptor, a process regulated upstream by the transcription factor Sp1 and the microRNA miR-29b. Specifically, miR-29b acts as a brake by inhibiting Sp1, which in turn reduces FUT4 expression and subsequent CD44 fucosylation.
Impact on Wnt/β-catenin Signaling and Malignancy
The study demonstrates that fucosylated CD44 is essential for activating the Wnt/β-catenin pathway, a major driver of oncogenic growth. When this axis is disrupted—either by inhibiting the Wnt pathway (via DKK), knocking down FUT4 (via shFUT4), or using a fucose-binding lectin (LTL)—downstream signaling proteins such as p-GSK-3β, β-catenin, and CyclinD1 are significantly downregulated.
Functional assays confirm that suppressing this pathway reduces the malignancy of LSCs. There is a marked decrease in colony formation and cell proliferation (measured by Ki67). Crucially, blocking the Wnt/fucosylation axis triggers programmed cell death (apoptosis), as evidenced by a significant rise in Annexin V-positive cells.
Conclusion
The correction of Figure 5 preserves the integrity of the original research, confirming that the miR-29b/Sp1/FUT4 axis is a vital regulator of LSC malignancy in AML. By linking protein glycosylation (fucosylation) to the Wnt/β-catenin pathway, the study highlights potential new therapeutic targets for eradicating the stem cell "seeds" of leukemia and preventing patient relapse. Future research will likely focus on in vivo validation and the translational potential of targeting the FUT4/fucosylation axis in clinical settings.
Summary updated